返回 
加入收藏
华蟾素胶囊联合放射治疗用于中晚期鼻咽癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 华蟾素胶囊联合放射治疗用于中晚期鼻咽癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨华蟾素胶囊联合放射治疗用于中晚期鼻咽癌患者的临床疗效及安全性。方法：回顾性分析我院肿瘤中心2011－2012年中晚期鼻咽癌患者95例，按治疗方案分为对照组（57例）和观察组（38例）。对照组患者接受单纯放射治疗，观察组患者在对照组基础上加服华蟾素胶囊0.5 g，tid，4周为1个疗程， 直至放疗结束。比较两组放射治疗时间延长情况，观察两组患者临床总有效率及随访1、3年的生存率和不良反应发生情况。结果：对照组放射治疗时间延长患者比例为89.47％，显著高于观察组的52.63％，差异有统计学意义（P＜0.05）。治疗结束时和治疗结束后1个月，观察组患者临床总有效率分别为81.58％、63.16％，显著高于对照组的70.18％和45.61％，差异均有统计学意义（P＜0.05）。观察组患者3～4级白细胞下降、血红蛋白下降、放疗局部副反应、鼻咽部的吞咽困难/疼痛等发生率显著低于对照组，差异均有统计学意义（P＜0.05）。随访第1、3年两组患者生存率比较，差异无统计学意义（P＞0.05）。结论：华蟾素胶囊联合放射治疗用于中晚期鼻咽癌患者疗效显著，可明显减轻急性放疗副反应，但尚未发现对患者生存率的提高。 |
| ABSTRACT： | OBJECTIVE： To investigate the clinical efficacy and safety of Cinobufacin capsules combined with radiotherapy in the treatment of median and advanced nasopharyngeal carcinoma. METHODS： Ninety-five patients with median and advanced nasopharyngeal carcinoma in cancer center of our hospital during 2011-2012 were analyzed retrospectively， and then divided into control group （57 cases） and observation group （38 cases） according to therapy plan. Control group received radiotherapy alone， while observation group was additionally given Cinobufacin capsule 0.5 g， tid， till the end of radiotherapy. A treatment course lasted for 4 weeks. The prolonged radiotherapy were compared between 2 groups. Clinical response rate was observed in 2 group， and 1-year and 3-year survival rate and the occurrence of ADR were followed up. RESULTS： The proportion of prolonged radiotherapy was 89.47％ in control group， which was significantly higher than 52.63％ of observation group， with statistical significance （P＜0.05）. At the end of therapy and one month after therapy， clinical total response rates of observation group were 81.58％ and 63.16％， which were significantly higher than 70.18％ and 45.61％ of control group， with statistical significance （P＜0.05）. The incidence of white blood cell lowering， hemoglobin lowering， local side effect of radiotherapy， nasopharyngeal dysphagia/odynophagia in observation group were significantly lower than in control group， with statistical significance （P＜0.05）. There was no statistical significance in survival rate between 2 groups in 1st-year and 3rd-year follow-up （P＞0.05）. CONCLUSIONS： Cinobufacin capsule combined with radiotherapy can significantly relieve the side effects of radiotherapy in median and advanced nasopharyngeal carcinoma patients. |
| 期刊： | 2017年第28卷第5期 |
| 作者： | 雷金华，喻雄杰，狄全书，吴何兴，李欣慧，曹凤军 |
| AUTHORS： | LEI Jinhua，YU Xiongjie，DI Quanshu，WU Hexing，LI Xinhui，CAO Fengjun |
| 关键字： | 鼻咽癌；放射治疗；华蟾素胶囊； 临床疗效；不良反应 |
| KEYWORDS： | Nasopharyngeal carcinoma； Radiotherapy； Cinobufacin capsule； Clinical efficacy； ADR |
| 阅读数： | 298 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
